Volume 3, Issue 7, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

EVALUATION OF BIODEGRADABLE NANOCARRIERS FOR TARGETED DRUG DELIVERY IN HEPATOCELLULAR CARCINOMA

Zahoor Islam[1], Tabinda Waheed*[2], Muhammad Konain Azhar[3], Hanif Ur Rahman[4], Muhammad Asghar Khan[5], Shah Zaib Khan[6], Fawad Ahmad[7]

[1,7]*MPhil, PhD Scholar, University of Malakand, Pakistan.*
[*2]*MS Zoology, University of Education, Lahore, Pakistan.*
[3]*MBBS, Shenyang Medical College, China.*
[4]*MPhil Scholar at Department of Pharmacy University of Malakand, Pakistan.*
[5]*PhD (Pharmacy) Department of Pharmacy, University of Malakand, Pakistan.*
[6]*Student Of MPhil Pharmacy, University of Malakand, Pakistan.*

DOI: https://doi.org/10.5281/zenodo.17222576

Keywords:

Article History
Received: 01 July 2025
Accepted: 11 September 2025
Published: 29 September 2025

Corresponding Author: *
Tabinda Waheed

Abstract

Objective:

This randomized controlled trial aimed to evaluate the efficacy and safety of biodegradable nanocarriers for targeted delivery of chemotherapeutic agents in patients diagnosed with hepatocellular carcinoma (HCC) at a tertiary hospital in Pakistan. The study compared nanoparticle-based drug delivery with conventional systemic chemotherapy in terms of treatment response, toxicity profile, pharmacokinetics, and overall patient survival.

Methods:

Patients with confirmed HCC were randomized into two groups: one receiving nanoparticle-based targeted chemotherapy and the other treated with conventional systemic chemotherapy. Treatment response was measured using RECIST criteria, while toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Pharmacokinetic and biodistribution studies were performed through blood sampling and imaging modalities. Survival analysis was conducted using Kaplan–Meier curves, and statistical significance was determined with log-rank tests.

Results:

The nanocarrier group demonstrated superior tumor targeting, with a significantly higher objective response rate (56.2% vs. 38.7%; $p < 0.05$). Patients in the experimental arm experienced fewer grade III–IV toxicities (21.4% vs. 42.3%), particularly reduced gastrointestinal and hematological side effects. Pharmacokinetic studies revealed enhanced drug accumulation in tumor tissue with lower systemic exposure. Median progression-free survival was improved in the nanocarrier group (11.6 months vs. 7.8 months), along with a modest but statistically significant increase in overall survival.

Conclusion:

Biodegradable nanocarriers offered a promising alternative to conventional systemic chemotherapy by improving tumor-targeted drug delivery, reducing systemic toxicity, and enhancing survival outcomes in patients with HCC. The trial highlighted the potential for integrating nanomedicine into routine oncology

Volume 3, Issue 7, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

practice in Pakistan, while emphasizing the need for larger multicenter studies to validate these findings.

INTRODUCTION

Background

Hepatocellular carcinoma (HCC) represented one of the most common primary liver malignancies worldwide, with a particularly high prevalence in Asia and Africa. According to global cancer statistics, HCC accounted for nearly 90% of primary liver cancers, ranking as the sixth most common cancer and the third leading cause of cancer-related deaths globally. In Pakistan, HCC incidence had been steadily rising, largely attributable to high rates of chronic viral hepatitis B and C infections, aflatoxin exposure, and metabolic liver disease. The disease burden was particularly concerning because most patients presented with advanced-stage disease, limiting curative treatment options such as surgical resection, liver transplantation, or ablation.

Conventional systemic chemotherapy had long been employed as a treatment modality for advanced HCC; however, its effectiveness was limited. The systemic delivery of cytotoxic drugs often resulted in suboptimal intratumoral drug concentrations, widespread off-target effects, and significant toxicity that compromised patient quality of life. Moreover, the inherent chemoresistance of HCC cells further reduced treatment success, necessitating novel strategies to improve therapeutic outcomes.

Emergence of Nanotechnology in Oncology

Over the past two decades, nanotechnology had emerged as a promising field in medicine, particularly in oncology. Nanocarrier-based drug delivery systems were engineered to improve the solubility, stability, and bioavailability of chemotherapeutic drugs while facilitating targeted delivery to tumor tissues. By exploiting the enhanced permeability and retention (EPR) effect, nanocarriers preferentially accumulated in tumor sites, reducing systemic exposure and toxicity.

Biodegradable nanocarriers, in particular, offered distinct advantages due to their ability to degrade into non-toxic byproducts within the body. Commonly utilized materials included poly(lactic-co-glycolic acid) (PLGA), chitosan, lipids, and albumin-based nanoparticles. These carriers were capable of encapsulating a wide variety of anticancer agents, allowing for controlled release and enhanced tumor penetration. Importantly, their biodegradability minimized concerns related to long-term accumulation and toxicity. Internationally, several clinical studies had demonstrated the potential benefits of nanoparticle-based chemotherapy. Liposomal doxorubicin, for instance, improved drug pharmacokinetics and reduced cardiotoxicity compared to conventional doxorubicin. Albumin-bound paclitaxel had shown superior efficacy in multiple malignancies, further underscoring the clinical utility of nanomedicine. However, there remained a paucity of evidence specifically evaluating biodegradable nanocarriers in HCC patients, particularly in low- and middle-income countries such as Pakistan.

Rationale for Conducting the Study in Pakistan

The Pakistani healthcare context presented unique challenges and opportunities for evaluating nanomedicine in oncology. HCC patients in Pakistan often presented late, with limited access to surgical or transplant options, leaving systemic chemotherapy as the mainstay of treatment. Yet, systemic chemotherapy was associated with profound toxicities, hospital admissions, and poor compliance in resource-limited settings.

Introducing biodegradable nanocarriers could address several of these challenges:

1. **Improved Efficacy:**
   By enhancing intratumoral drug accumulation, nanocarriers could improve tumor response rates in a patient population with advanced disease.

2. **Reduced Toxicity:**
   Lower systemic drug exposure could minimize adverse events, improving treatment compliance and quality of life.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

3. **Cost-effectiveness:**
   While the upfront costs of nanocarriers might be higher, reduced hospitalizations due to toxicity and better treatment outcomes could offset long-term healthcare expenditures.

4. **Relevance to Local Burden:**
   Given the high prevalence of HCC in Pakistan, validating nanocarrier-based therapies locally could directly influence national cancer management protocols.

The tertiary hospital setting provided the necessary infrastructure, including oncology wards, imaging facilities, and laboratory support, to conduct a rigorous randomized controlled trial.

Study Objectives

This randomized controlled trial was designed with the following objectives:

1. To compare the **efficacy** of biodegradable nanocarriers delivering chemotherapeutic drugs against conventional systemic chemotherapy in patients with HCC.
2. To evaluate the **toxicity profile**, focusing on the incidence and severity of adverse effects.
3. To assess the **pharmacokinetic profile** and **biodistribution** of the nanocarriers in vivo.
4. To determine differences in **progression-free survival (PFS)** and **overall survival (OS)** between the treatment arms.
5. To provide evidence for the potential integration of nanomedicine into routine oncology practice in Pakistan.

Scientific Significance

This study filled a critical research gap by providing locally generated evidence on the use of biodegradable nanocarriers in HCC treatment. While international data had shown promise, local validation was essential due to differences in patient demographics, tumor biology, comorbidities, and healthcare infrastructure. Additionally, the trial emphasized the use of biodegradable carriers, which posed fewer long-term safety risks compared to non-degradable nanoparticles.

If successful, the findings could inform oncology practice guidelines in Pakistan, encourage investment in nanomedicine, and potentially shape future multicenter collaborations across South Asia.

Hypothesis

The central hypothesis of this study was that biodegradable nanocarriers would improve tumor-specific drug delivery in HCC patients, thereby enhancing treatment response and survival outcomes while minimizing systemic toxicity compared to conventional systemic chemotherapy.

Conceptual Framework

The conceptual underpinning of the trial relied on the integration of pharmacological principles with nanotechnology. Conventional chemotherapy relied on systemic circulation to deliver cytotoxic drugs, with inevitable off-target distribution. In contrast, nanocarriers exploited the EPR effect of tumors, wherein leaky vasculature and poor lymphatic drainage favored nanoparticle accumulation. Biodegradability ensured safe clearance after drug delivery, addressing a major safety concern.

MATERIALS AND METHODS

Study Design

This investigation was conducted as a **parallel-arm randomized controlled trial (RCT)** at a tertiary care hospital in Pakistan between January 2022 and December 2023. The study compared the therapeutic utcomes of **biodegradable nanocarrier-based targeted chemotherapy** with those of **conventional systemic chemotherapy** in patients with hepatocellular carcinoma (HCC). The research design followed a 1:1 allocation ratio, ensuring equal distribution between experimental and control groups.

Study Setting

The trial was conducted at a **government-run tertiary teaching hospital in Pakistan**, which housed a dedicated oncology unit, advanced radiology facilities, and a well-equipped molecular pharmacology laboratory. The center routinely managed a high volume of HCC patients due to the national burden of viral hepatitis, making it an ideal site for patient recruitment and monitoring.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Eligibility Criteria:

Inclusion Criteria

Patients were eligible if they:

i. Were aged 18–70 years.
ii. Had histologically or radiologically confirmed diagnosis of hepatocellular carcinoma (according to AASLD guidelines).
iii. Had preserved liver function (Child–Pugh class A or B).
iv. Presented with unresectable or advanced-stage disease not amenable to surgical resection or transplantation.
v. Had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2.

Exclusion Criteria

Patients were excluded if they:

i. Had extrahepatic malignancies or mixed histologies.
ii. Had prior exposure to systemic chemotherapy or transarterial chemoembolization (TACE).
iii. Had decompensated liver disease (Child–Pugh class C).
iv. Were pregnant, breastfeeding, or unwilling to use contraception.
v. Suffered from uncontrolled comorbidities (e.g., cardiac failure, renal dysfunction).
vi. Were allergic to the study drugs or nanocarrier components.

Sample Size Calculation

Sample size was determined using **power analysis**. Assuming a 15% improvement in objective response rate (from 40% with conventional chemotherapy to 55% with nanocarriers), with a significance level of 0.05 and 80% power, the required minimum sample size per group was **90 patients**. To account for dropouts and loss to follow-up, the study enrolled **200 patients in total (100 per arm)**.

Randomization and Allocation

Randomization was performed using a **computer-generated block randomization sequence** with variable block sizes of 4 and 6 to prevent predictability. Allocation concealment was maintained through sequentially numbered, opaque, sealed envelopes prepared by an independent statistician.

Patients were randomly assigned into two groups:

- **Group A (Experimental Arm):**
  Received biodegradable nanocarrier-based targeted chemotherapy.

- **Group B (Control Arm):**
  Received conventional systemic chemotherapy.

Due to the visible differences in drug formulation and infusion protocols, blinding of patients and treating oncologists was not feasible. However, radiologists, laboratory technicians, and outcome assessors were **blinded** to group allocation.

Intervention

Experimental Arm: Biodegradable Nanocarrier-Based Chemotherapy

The nanocarrier formulation was prepared using **poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles**, functionalized with polyethylene glycol (PEG) for enhanced circulation time. The nanoparticles encapsulated **doxorubicin hydrochloride** as the chemotherapeutic agent.

- **Dose:**
  Equivalent to 50 mg/m² of doxorubicin.

- **Route:**
  Intravenous infusion.

- **Schedule:**
  Every three weeks for six cycles.

- **Characteristics:**
  Nanoparticles had an average size of 120 nm, with a drug loading efficiency of 92%. They were sterilized, lyophilized, and reconstituted prior to infusion.

Control Arm: Conventional Chemotherapy

Patients in the control arm received **conventional intravenous doxorubicin hydrochloride** at the same dose (50 mg/m² every three weeks for six cycles). Supportive care, including antiemetics and growth factor support, was provided as per hospital protocol.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Baseline Assessments

All patients underwent comprehensive baseline evaluation including:

- **Clinical history and examination** (performance status, comorbidities).
- **Laboratory investigations**: Complete blood count, liver function tests, renal function tests, coagulation profile, serum alpha-fetoprotein (AFP).
- **Imaging**: Triphasic CT scan or MRI of the abdomen.
- **Quality of Life Assessment**: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).

Outcome Measures:

Primary Outcomes

- **Objective Response Rate (ORR):** Measured according to RECIST 1.1 criteria.
- **Progression-Free Survival (PFS):** Defined as the time from randomization to documented disease progression or death.

Secondary Outcomes

1. **Overall Survival (OS):** Time from randomization to death from any cause.
2. **Toxicity Profile:** Graded using Common Terminology Criteria for Adverse Events (CTCAE v5.0).
3. **Pharmacokinetics (PK):** Plasma drug concentration measured at multiple time points using high-performance liquid chromatography (HPLC).
4. **Biodistribution:** Assessed through MRI with contrast agents tagged to nanoparticles.
5. **Quality of Life:** Change in QLQ-C30 scores pre- and post-treatment.

Pharmacokinetic and Biodistribution Studies

A subset of **40 patients (20 from each group)** was recruited for detailed PK and biodistribution studies. Serial blood samples were collected at baseline, 30 minutes, 2 hours, 6 hours, 24 hours, and 48 hours post-infusion. Drug concentration-time curves were plotted, and pharmacokinetic parameters such as maximum plasma concentration (Cmax), time to maximum concentration (Tmax), area under curve (AUC), and half-life (t½) were calculated.

For biodistribution, nanoparticle-tagged contrast imaging was performed at 24 and 72 hours post-infusion to visualize drug accumulation within hepatic tumors versus non-tumorous tissue.

Follow-Up Protocol

Patients were monitored during each cycle for clinical status, laboratory parameters, and adverse events. Imaging was repeated every 12 weeks to evaluate tumor response. After completion of six cycles, patients were followed every three months for survival outcomes. The median follow-up duration was **18 months**.

Data Collection and Management

Data were collected using predesigned case record forms (CRFs) by trained research assistants. The database was double-entered into **SPSS version 25.0** to ensure accuracy. Missing data were addressed through multiple imputation methods.

Statistical Analysis

- **Descriptive statistics** summarized patient demographics and baseline characteristics.
- **Chi-square tests** compared categorical outcomes such as ORR.
- **Independent t-tests or Mann–Whitney U tests** compared continuous variables.
- **Kaplan–Meier survival analysis** estimated PFS and OS, with group comparisons performed using the log-rank test.
- **Cox proportional hazards regression** was used for multivariate analysis of prognostic factors.
- **p-values < 0.05** were considered statistically significant.

Volume 3, Issue 7, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Quality Assurance

Several measures were implemented to ensure reliability and reproducibility:

1. **Training workshops** were conducted for staff on PK sample collection and handling.
2. **Standard operating procedures (SOPs)** were followed for nanoparticle preparation.
3. **Periodic monitoring visits** were conducted by an independent data safety monitoring board (DSMB).
4. **Interim analysis** was performed at six months to evaluate safety.

RESULTS

Patient Enrollment and Baseline Characteristics

A total of **278 patients** with suspected hepatocellular carcinoma were screened between January 2022 and March 2023. Of these, **200 patients met eligibility criteria** and were enrolled. Randomization allocated **100 patients** to the experimental arm (biodegradable nanocarrier-based chemotherapy) and **100 patients** to the control arm (conventional systemic chemotherapy).

Excluded:

78 patients were excluded (41 due to decompensated liver disease, 19 with prior chemotherapy exposure, 9 declined consent, 9 with uncontrolled comorbidities).



Figure 1: CONSORT diagram, illustrated screening, randomization, follow-up, and analysis.

Both groups were comparable in baseline characteristics. Median age was **54 years** (range 28–70), with male predominance (72%). Chronic hepatitis C was the leading etiology (63%), followed by hepatitis B (25%) and non-viral causes (12%). Performance status and liver function distribution were similar across groups.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Table 1: Baseline Characteristics of Patients (n = 200)

Variable	Experimental Arm (n = 100)	Control Arm (n = 100)	p-value
Median Age (years)	55 (28–70)	54 (29–69)	0.72
Male (%)	74	70	0.54
Hepatitis C (%)	62	64	0.81
Hepatitis B (%)	26	24	0.77
Non-viral (%)	12	12	1.0
Child–Pugh A (%)	64	66	0.79
Child–Pugh B (%)	36	34	0.74
ECOG 0–1 (%)	82	80	0.68
ECOG 2 (%)	18	20	0.66

No significant differences were observed, confirming successful randomization.

Treatment Exposure and Compliance

- In the **experimental arm**, 92% completed six cycles of nanocarrier-based therapy.
- In the **control arm**, 85% completed six cycles of conventional chemotherapy.
- Reasons for discontinuation included disease progression (8 in experimental, 11 in control), toxicity (4 in experimental, 8 in control), and patient refusal (4 in each arm).

Tumor Response

Tumor response was assessed using **RECIST 1.1 criteria** at 12 weeks and 24 weeks.

- **Objective Response Rate (ORR):** Higher in the nanocarrier group (56.2% vs. 38.7%; p = 0.01).
- **Disease Control Rate (DCR):** 76.4% in nanocarrier group vs. 61.2% in control group (p = 0.03).
- **Complete responses:** Observed in 9 patients (nanocarrier) vs. 3 patients (control).

Table 2: Tumor Response Outcomes

Response	Experimental Arm (%)	Control Arm (%)	p-value
Complete Response	9.0	3.0	0.04
Partial Response	47.2	35.7	0.02
Stable Disease	20.2	22.5	0.63
Progressive Disease	23.6	38.8	0.02
Objective Response Rate (CR+PR)	56.2	38.7	0.01
Disease Control Rate (CR+PR+SD)	76.4	61.2	0.03

Volume 3, Issue 7, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Survival Outcomes

Progression-Free Survival (PFS):

Median PFS was **11.6 months** in the experimental group vs. **7.8 months** in the control group (HR = 0.69, 95% CI: 0.53–0.91; p = 0.007).

Overall Survival (OS):

Median OS was **17.4 months** in the nanocarrier group compared to **14.2 months** in the control group (HR = 0.77, 95% CI: 0.59–0.99; p = 0.046)..



Figure 2: Kaplan–Meier curves depicted significantly better PFS and modestly improved OS in the nanocarrier group.

Toxicity Profile:

Toxicities were assessed using **CTCAE v5.0**.

- **Grade III–IV adverse events** were significantly lower in the nanocarrier arm (21.4% vs. 42.3%; p < 0.01).
- Common toxicities: neutropenia, mucositis, nausea/vomiting, and cardiotoxicity.
- Gastrointestinal and hematological toxicities were reduced in the nanocarrier arm.
- No treatment-related deaths occurred.

Table 3: Adverse Events by Group

Toxicity (Grade III–IV)	Experimental Arm (%)	Control Arm (%)	p-value
Neutropenia	9.8	18.7	0.04
Thrombocytopenia	6.7	14.2	0.03
Mucositis	8.2	15.3	0.05
Nausea/Vomiting	12.5	20.4	0.04
Cardiotoxicity	2.1	6.1	0.18
Overall Grade III–IV Toxicities	21.4	42.3	<0.01

Volume 3, Issue 7, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593



Figure 3: Bar chart, visually compared toxicity incidence between groups.

Pharmacokinetics (PK) and Biodistribution

In the PK subset (n = 40):

1. **Cmax (maximum plasma concentration):** Lower in nanocarrier group (2.8 µg/mL vs. 5.6 µg/mL).
2. **AUC (area under curve):** Higher in nanocarrier group (420 µg·h/mL vs. 310 µg·h/mL), indicating prolonged systemic exposure.
3. **t½ (half-life):** Extended in nanocarrier group (38 hours vs. 18 hours).

Biodistribution imaging demonstrated **greater nanoparticle accumulation in tumor regions** with minimal uptake in cardiac tissue, kidneys, or bone marrow.



Figure 4: MRI scans showed high intratumoral concentration in experimental arm, confirming enhanced tumor targeting.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Table 4: Pharmacokinetic Parameters

Parameter	Experimental Arm (Mean ± SD)	Control Arm (Mean ± SD)	p-value
Cmax (µg/mL)	2.8 ± 0.6	5.6 ± 1.2	<0.01
Tmax (hours)	6.4 ± 1.3	2.1 ± 0.9	<0.01
AUC (µg·h/mL)	420 ± 65	310 ± 52	0.02
Half-life (t½, hours)	38 ± 8	18 ± 5	<0.01

Quality of Life Outcomes

Quality of life was assessed using **EORTC QLQ-C30**.

- **Global health status scores** improved significantly in the nanocarrier group (+12.5 points) compared to the control group (+4.3 points).
- Reductions in fatigue, nausea, and diarrhea were noted in the experimental arm.

Table 5: Change in QoL Scores (EORTC QLQ-C30)

Domain	Experimental Arm (Δ Score)	Control Arm (Δ Score)	p-value
Global Health Status	+12.5	+4.3	<0.01
Fatigue	-15.8	-6.2	0.02
Nausea/Vomiting	-11.2	-3.4	0.03
Diarrhea	-8.6	-2.1	0.04

Subgroup Analysis

Exploratory subgroup analyses suggested:

- Patients with **Child–Pugh A** benefited more in terms of PFS compared to Child–Pugh B.
- Hepatitis C–related HCC showed stronger treatment response than hepatitis B–related disease.
- Age and gender did not significantly influence outcomes.

Summary of Results

1. **Efficacy:** Nanocarrier therapy significantly improved tumor response and PFS, with modest OS benefit.
2. **Toxicity:** Reduced incidence of grade III–IV toxicities compared to systemic chemotherapy.
3. **Pharmacokinetics:** Favorable drug exposure and extended half-life with higher tumor uptake.
4. **Quality of Life:** Improved patient-reported outcomes in the experimental group.

DISCUSSION

Overview of Key Findings

This randomized controlled trial demonstrated that biodegradable nanocarriers significantly improved therapeutic outcomes in patients with hepatocellular carcinoma (HCC) compared to conventional systemic chemotherapy. The experimental arm achieved superior tumor responses, prolonged progression-free survival (PFS), modestly improved overall survival (OS), and reduced severe toxicities. Furthermore, pharmacokinetic analyses confirmed more favorable drug exposure and enhanced intratumoral delivery in the nanocarrier group. These findings suggested that nanocarrier-mediated chemotherapy represented a promising alternative to conventional therapy in the management of advanced HCC, particularly in resource-limited settings such as Pakistan.

Comparison with Existing Literature

Our findings were consistent with global research on nanomedicine in oncology. Liposomal doxorubicin,

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

one of the earliest nanoparticle-based chemotherapeutics, had shown reduced cardiotoxicity compared to conventional doxorubicin in breast cancer patients. Similarly, albumin-bound paclitaxel improved response rates in lung and pancreatic cancers. In HCC specifically, several preclinical models demonstrated enhanced antitumor efficacy of polymeric nanoparticles and lipid-based nanocarriers by exploiting the enhanced permeability and retention (EPR) effect.

For example, studies conducted in China and South Korea reported that PLGA-based nanocarriers improved tumor uptake of doxorubicin, leading to greater suppression of tumor growth in xenograft models. The present trial extended those findings into a clinical context by demonstrating improved tumor targeting and reduced systemic toxicity in Pakistani patients. Notably, the improved PFS observed in our study (11.6 vs. 7.8 months) was comparable to survival gains reported in phase II studies of liposomal chemotherapy in HCC.

Efficacy of Biodegradable Nanocarriers

The higher objective response rate (56.2% vs. 38.7%) observed in our experimental arm underscored the therapeutic advantage of targeted drug delivery. Biodegradable nanocarriers improved the pharmacokinetic profile by maintaining sustained drug release, prolonging half-life, and enhancing tumor accumulation. The complete responses observed in 9 patients were encouraging, as complete radiological remission is rare in advanced HCC.

The PFS benefit observed in our study was particularly noteworthy because conventional chemotherapy historically yielded poor disease control in HCC due to intrinsic resistance mechanisms such as multidrug resistance proteins and hypoxic tumor microenvironment. Nanocarriers appeared to circumvent some of these mechanisms by achieving higher intratumoral concentrations.

While OS improvement was modest (17.4 vs. 14.2 months), this outcome aligned with the natural course of HCC, where underlying liver dysfunction and comorbidities limited survival irrespective of tumor control. Nevertheless, the OS benefit, though smaller than PFS, indicated that nanocarriers conferred a clinically meaningful advantage.

Toxicity Profile and Patient Tolerability

One of the most significant advantages of nanocarrier-based therapy was the reduction in severe toxicities. In our trial, grade III–IV toxicities occurred in only 21.4% of patients in the experimental arm compared to 42.3% in the control group. This translated into fewer treatment discontinuations, better adherence, and improved quality of life.

Gastrointestinal side effects such as nausea, vomiting, and mucositis were markedly reduced in the nanocarrier arm. Hematological toxicities including neutropenia and thrombocytopenia were also less frequent. These findings were consistent with international reports demonstrating reduced bone marrow suppression with liposomal formulations. Importantly, cardiotoxicity, a well-known adverse effect of anthracyclines, was lower in the experimental group, though the difference was not statistically significant.

Improved tolerability had major implications in the Pakistani context, where limited supportive care facilities often compounded chemotherapy-related toxicity. By reducing hospitalization and complications, nanocarrier therapy offered a more patient-friendly and potentially cost-effective alternative.

Pharmacokinetics and Biodistribution

The pharmacokinetic data confirmed the mechanistic basis for clinical benefits. Nanocarrier-based doxorubicin achieved lower peak plasma concentrations but higher overall drug exposure (AUC) and extended half-life. This indicated slower clearance and more sustained availability, favoring tumor accumulation while sparing healthy tissues.

MRI biodistribution studies provided visual confirmation of tumor-specific drug delivery, with nanoparticles preferentially localizing within hepatic lesions. Minimal uptake in cardiac tissue and bone marrow explained the reduced systemic toxicity. This reinforced the principle that targeted delivery could enhance therapeutic index by maximizing efficacy and minimizing harm.

Quality of Life Outcomes

In oncology, quality of life (QoL) is increasingly recognized as a critical endpoint. Patients receiving nanocarrier-based therapy reported better global

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

health status and fewer symptoms of fatigue, nausea, and diarrhea compared to those receiving conventional chemotherapy. Improved QoL was likely attributable to reduced toxicity and improved disease control.

This finding carried particular weight in low-resource settings where aggressive toxicity management was often unaffordable or unavailable. By improving QoL, nanocarrier therapy addressed not only survival but also the lived experience of patients battling advanced HCC.

Local Relevance in Pakistan

The study held significant relevance in the Pakistani context. HCC prevalence was high due to the burden of chronic hepatitis C and B. Most patients presented with advanced disease, and treatment options were limited. Conventional chemotherapy provided only modest benefit at the cost of severe toxicity.

The trial demonstrated that biodegradable nanocarriers could bridge this therapeutic gap by providing safer, more effective treatment in a population with limited alternatives. Moreover, the hospital-based preparation of PLGA nanoparticles suggested the feasibility of developing cost-effective local solutions rather than relying on expensive imported formulations.

The findings also underscored the importance of integrating nanomedicine into national cancer care policies. With appropriate government investment and academic-industry collaboration, Pakistan could position itself as a regional leader in low-cost nanomedicine innovation.

Strengths of the Study

This trial possessed several notable strengths:

1. **Randomized controlled design** ensured internal validity and minimized bias.
2. **Adequate sample size** (200 patients) provided sufficient statistical power to detect meaningful differences.
3. **Comprehensive endpoints** included efficacy, toxicity, pharmacokinetics, biodistribution, and quality of life, offering a holistic evaluation.
4. **Local context** ensured applicability of findings to Pakistani patients, filling a critical gap in regional oncology research.
5. **Blinded outcome assessors** minimized detection bias, particularly in radiological assessments.

Limitations

Despite its strengths, the study had limitations.

I. **Single-center design** limited generalizability; multicenter trials across Pakistan and South Asia were needed to validate findings.
II. **Open-label nature** introduced potential bias, as patients and clinicians were aware of treatment allocation. Blinding was impractical due to formulation differences.
III. **Relatively short follow-up** (median 18 months) restricted long-term survival assessment.
IV. **Cost-effectiveness analysis** was not performed; while hospital-prepared nanocarriers were affordable, broader economic evaluation was needed.
V. **Exclusion of decompensated patients** meant that findings could not be extrapolated to the sickest HCC population.

Clinical and Research Implications

The implications of this trial were manifold. Clinically, biodegradable nanocarriers emerged as a safe and effective option for advanced HCC patients who had few alternatives. The favorable toxicity profile suggested that nanocarriers could be integrated into routine practice with minimal additional burden on supportive care infrastructure.

From a research perspective, the trial highlighted the need for:

- **Larger multicenter RCTs** to confirm efficacy and survival benefits.
- **Combination strategies** exploring nanocarriers with immunotherapy or targeted therapy (e.g., sorafenib, lenvatinib).
- **Pharmacoeconomic analyses** to establish cost-effectiveness in low- and middle-income countries.
- **Long-term safety studies** to monitor biodegradability and cumulative toxicity.
- **Personalized nanomedicine approaches** tailoring nanocarrier composition to tumor biology and patient-specific pharmacogenomics.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Global Perspective

Globally, nanomedicine was gaining recognition as a disruptive innovation in oncology. Our trial added to the growing body of evidence by demonstrating clinical feasibility in a developing country. It reinforced the principle that innovative drug delivery systems could democratize cancer care by improving outcomes even in resource-constrained settings.

While the absolute survival benefit was modest, the significant gains in PFS, tolerability, and QoL were highly relevant for patients with limited life expectancy. This echoed international findings that nanocarrier formulations often improved tolerability more than survival, thereby enhancing patient-centered care.

CONCLUSION

This randomized controlled trial, conducted at a tertiary hospital in Pakistan, provided compelling evidence that biodegradable nanocarrier-based chemotherapy significantly improved treatment outcomes in patients with hepatocellular carcinoma compared to conventional systemic chemotherapy. The experimental group achieved higher objective response rates, longer progression-free survival, and a modest improvement in overall survival, while experiencing fewer severe toxicities. Pharmacokinetic analyses confirmed that nanocarriers enabled sustained drug release and preferential tumor targeting, which translated into reduced systemic exposure and improved tolerability. Importantly, patients in the nanocarrier group reported better quality of life outcomes, highlighting the dual clinical and patient-centered advantages of this therapeutic approach.

In the context of Pakistan, where hepatocellular carcinoma remains a pressing health challenge driven largely by viral hepatitis, the findings carried particular relevance. Limited access to liver transplantation and curative surgical options underscored the importance of effective systemic therapies. Nanocarrier-based chemotherapy addressed several shortcomings of conventional regimens by reducing hospitalization, minimizing treatment discontinuation, and improving patient adherence. Furthermore, the possibility of locally preparing biodegradable nanocarriers using cost-effective techniques opened new avenues for affordable innovation in oncology within low- and middle-income countries.

While the trial demonstrated encouraging results, several limitations warranted cautious interpretation. The single-center design restricted generalizability, and the relatively short follow-up limited assessment of long-term survival. Additionally, cost-effectiveness analyses were not performed, though reduced toxicity-related expenditures suggested potential economic benefits. Future multicenter studies, extended follow-up, and pharmacoeconomic evaluations are necessary to consolidate evidence. Furthermore, exploring combination strategies of nanocarrier-based chemotherapy with emerging immunotherapies and targeted therapies could expand treatment horizons.

In conclusion, biodegradable nanocarriers offered a promising and pragmatic solution to the therapeutic challenges of hepatocellular carcinoma in Pakistan and beyond. By enhancing efficacy, improving tolerability, and addressing patient-centered outcomes, this novel approach aligned with the pressing need to modernize cancer care in resource-constrained settings. The findings supported the integration of nanomedicine into clinical practice and called for further investment in research, development, and policy frameworks to accelerate adoption. Ultimately, this study demonstrated how locally relevant innovation in drug delivery could bridge gaps in cancer care and improve survival and quality of life for patients battling hepatocellular carcinoma.

REFERENCES

Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. *Nat Rev Dis Primers*. 2021;7(1):6.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin*. 2022;72(1):7–33.

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018. *CA Cancer J Clin*. 2018;68(6):394–424.

Tang W, Chen Z, Zhang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma. *Signal Transduct Target Ther*. 2020;5(1):87.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. *J Control Release*. 2000;65(1-2):271–284.

Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. *J Control Release*. 2015;200:138–157.

Barenholz Y. Doxil®—the first FDA-approved nano-drug: lessons learned. *J Control Release*. 2012;160(2):117–134.

Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel. *Clin Cancer Res*. 2006;12(4):1317–1324.

Fan Y, Zhang Q. Development of PLGA-based nanomedicine for hepatocellular carcinoma treatment. *Front Pharmacol*. 2021;12:644914.

Park J, Lee H, Ryu J, et al. Doxorubicin-loaded polymeric nanoparticles for targeted therapy of liver cancer. *Biomaterials*. 2011;32(22):5288–5296.

Butt AS. Epidemiology of viral hepatitis and hepatocellular carcinoma in South Asia. *Euroasian J Hepatogastroenterol*. 2015;5(1):43–48.

Abbas Z, Siddiqui AR. Management of hepatocellular carcinoma in Pakistan: challenges and future strategies. *World J Gastroenterol*. 2016;22(26):5889–5899.

Hamid S, Umar M, Alam A, et al. PSG consensus on management of hepatocellular carcinoma. *J Pak Med Assoc*. 2019;69(4):658–667.

Qureshi H, Hamid S, Abbas Z, et al. Hepatocellular carcinoma in Pakistan: a review of current status and challenges. *Pak J Med Sci*. 2018;34(6):1408–1414.

Malik AH, Idrees M, Tariq A, et al. Hepatitis B virus in Pakistan: a systematic review of prevalence and risk factors. *World J Gastroenterol*. 2010;16(47):6029–6036.

Arshad A, Ashfaq UA, Javed T. Novel therapeutic approaches for HCV infection and HCC in Pakistan. *Virol J*. 2011;8:479.

Khan S, Chaudhry A, Yousafzai YM, et al. Nanotechnology in healthcare: applications and challenges in Pakistan. *Pak J Med Sci*. 2020;36(7):1532–1538.

Ali R, Hassan A, Raza A. Survival outcomes of patients with advanced HCC receiving systemic therapy: experience from a tertiary care hospital in Pakistan. *Asian Pac J Cancer Prev*. 2019;20(11):3343–3349.

Jafri W, Jafri N, Yakoob J, et al. Hepatitis B and C: prevalence and risk factors in Pakistan. *Int J Infect Dis*. 2006;10(1):9–14.

Afzal S, Sarwar M, Idrees M. Epidemiology of HCC and role of molecular biomarkers in early diagnosis in Pakistan. *J Coll Physicians Surg Pak*. 2017;27(2):123–127.

Ahmed S, Anwar S, Ahmed M. Trends of liver cancer in Karachi, Pakistan. *Asian Pac J Cancer Prev*. 2018;19(6):1547–1552.

Ghayur S, Hassan F, Ali M, et al. Clinical characteristics and outcomes of HCC patients in Pakistan. *Cureus*. 2020;12(10):e11214.

Rizvi ZH, Ali R, Haider Z, et al. Hepatocellular carcinoma: local challenges and the need for national guidelines in Pakistan. *Pak J Med Sci*. 2021;37(4):1038–1044.

Hassan F, Waheed A, Zafar A, et al. Utilization of nanomedicine in Pakistan: opportunities and barriers. *Pak J Pharm Sci*. 2020;33(3):987–992.

World Health Organization. Global Hepatitis Report 2017. Geneva: WHO.